MSWM
DNLI icon

Mowery & Schoenfeld Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Mowery & Schoenfeld Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Buy
555
+55
+11% +$1.13K 0.02% 214
2026
Q1 		$9.6K Buy
+500
New +$9.95K 0.01% 223

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mowery & Schoenfeld Wealth Management's DNLI Position: Q2 2026 in Review

Mowery & Schoenfeld Wealth Management increased its Denali Therapeutics (DNLI) stake by 11% in Q2 2026, buying an estimated $1.13K and bringing the position to 555 shares worth $14.3K. The position accounts for 0.02% of the portfolio, ranked #214.

Mowery & Schoenfeld Wealth Management first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Mowery & Schoenfeld Wealth Management held 555 shares of Denali Therapeutics worth $14.3K as of Q2 2026.
  • Mowery & Schoenfeld Wealth Management bought 55 Denali Therapeutics shares in Q2 2026, an estimated $1.13K.
  • Denali Therapeutics made up 0.02% of Mowery & Schoenfeld Wealth Management's portfolio in Q2 2026, its #214 holding.
  • Mowery & Schoenfeld Wealth Management first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Mowery & Schoenfeld Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.